Company Analysis
Sign in

Crescent Biopharma, Inc. (CBIO)

Nasdaq: CBIO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2003
Full chart Alerts Compare
Grade5.1
◀ Past 4.7● Present 4.8▶ Future 5.6
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

41 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Crescent Biopharma, Inc.’s names, not what it holds today.

Patents granted
41
40 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
none
Against 3 in 2024 and 5 in 2023
Applications published
89
since 2001, to Dec 31, 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
'10'11'12'13'14'15'16'17'18'19'20'21'22'23'24
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Organic fine chemistry5
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
GLYCOMIMETICS, INC. a former name
US, as the owner printed on each patent
41 granted
82 published
GLYCOMIMETICS, INC. a former name
named as the applicant on its applications, in US
0 granted
7 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
May 21, 202411,987,598E-selectin antagonist compounds, compositions, and methods of usePharmaceuticalsGLYCOMIMETICS, INC.
Jan 23, 202411,878,026Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonistsPharmaceuticalsGLYCOMIMETICS, INC.
Jan 16, 202411,873,317Galectin-3 inhibiting c-glycosidesOrganic fine chemistryGLYCOMIMETICS, INC.
Dec 19, 202311,845,771Heterobifunctional inhibitors of E-selectin and galectin-3Organic fine chemistryGLYCOMIMETICS, INC.
Oct 10, 202311,780,873Highly potent multimeric e-selectin antagonistsOrganic fine chemistryGLYCOMIMETICS, INC.
Aug 1, 202311,712,446Methods of mobilizing marrow infiltrating lymphocytes and uses thereofPharmaceuticalsGLYCOMIMETICS, INC.
Jul 25, 202311,707,474Methods for treating acute myeloid leukemia and related conditionsPharmaceuticalsGLYCOMIMETICS, INC.
Jan 10, 202311,548,908Heterobifunctional inhibitors of E-selectin and galectin-3Organic fine chemistryGLYCOMIMETICS, INC.
Sep 6, 202211,433,086Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4PharmaceuticalsGLYCOMIMETICS, INC.
May 17, 202211,332,491E-selectin antagonist compounds, compositions, and methods of usePharmaceuticalsGLYCOMIMETICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 19, 20242024/0417420POLAR CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERSOrganic fine chemistryGLYCOMIMETICS, INC.
Aug 29, 20242024/0287121GALECTIN-3 INHIBITING C-GLYCOSIDE OXIMESOrganic fine chemistryGLYCOMIMETICS, INC.
Aug 15, 20242024/0270724GALECTIN-3 INHIBITING C-GLYCOSIDESPharmaceuticalsGLYCOMIMETICS, INC.
Aug 15, 20242024/0269157COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETINGPharmaceuticalsGLYCOMIMETICS, INC.
May 23, 20242024/0165139GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTSPharmaceuticalsGLYCOMIMETICS, INC.
May 9, 20242024/0150388HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3Organic fine chemistryGLYCOMIMETICS, INC.
May 2, 20242024/0140976PROCESS FOR PREPARING AN E-SELECTIN INHIBITOR INTERMEDIATEOrganic fine chemistryGLYCOMIMETICS, INC.
Dec 28, 20232023/0414642METHODS OF MOBILIZING MARROW INFILTRATING LYMPHOCYTES AND USES THEREOFPharmaceuticalsGLYCOMIMETICS, INC.
Dec 28, 20232023/0414641METHODS FOR TREATING ACUTE MYELOID LEUKEMIA AND RELATED CONDITIONSPharmaceuticalsGLYCOMIMETICS, INC.
Nov 16, 20232023/0365609HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTSOrganic fine chemistryGLYCOMIMETICS, INC.
What it applied for, 2024 to 2025: Organic fine chemistry 4 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CBIO · research, not advice